JP7393206B2 - 腎機能代謝産物の検出及び定量化のための質量分析アッセイ方法 - Google Patents
腎機能代謝産物の検出及び定量化のための質量分析アッセイ方法 Download PDFInfo
- Publication number
- JP7393206B2 JP7393206B2 JP2019553158A JP2019553158A JP7393206B2 JP 7393206 B2 JP7393206 B2 JP 7393206B2 JP 2019553158 A JP2019553158 A JP 2019553158A JP 2019553158 A JP2019553158 A JP 2019553158A JP 7393206 B2 JP7393206 B2 JP 7393206B2
- Authority
- JP
- Japan
- Prior art keywords
- analytes
- mobile phase
- tryptophan
- creatinine
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004949 mass spectrometry Methods 0.000 title claims description 33
- 238000011002 quantification Methods 0.000 title description 54
- 230000003907 kidney function Effects 0.000 title description 8
- 238000003556 assay Methods 0.000 title description 6
- 239000002207 metabolite Substances 0.000 title description 4
- 238000001514 detection method Methods 0.000 title description 3
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 174
- 150000002500 ions Chemical class 0.000 claims description 170
- 238000000034 method Methods 0.000 claims description 155
- 229940109239 creatinine Drugs 0.000 claims description 87
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 78
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 77
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims description 77
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims description 77
- 229930185560 Pseudouridine Natural products 0.000 claims description 76
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims description 76
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 claims description 74
- 238000002347 injection Methods 0.000 claims description 48
- 239000007924 injection Substances 0.000 claims description 48
- PEDXUVCGOLSNLQ-WUJLRWPWSA-N N-acetyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(C)=O PEDXUVCGOLSNLQ-WUJLRWPWSA-N 0.000 claims description 40
- 102100028630 Cytoskeleton-associated protein 2 Human genes 0.000 claims description 36
- 101000766848 Homo sapiens Cytoskeleton-associated protein 2 Proteins 0.000 claims description 36
- WOERBKLLTSWFBY-UHFFFAOYSA-M dihydrogen phosphate;tetramethylazanium Chemical compound C[N+](C)(C)C.OP(O)([O-])=O WOERBKLLTSWFBY-UHFFFAOYSA-M 0.000 claims description 36
- 238000004811 liquid chromatography Methods 0.000 claims description 21
- QIVBCDIJIAJPQS-HLTLGYGQSA-N (2s)-2-amino-3-(2,4,5,6,7-pentadeuterio-1h-indol-3-yl)propanoic acid Chemical compound [2H]C1=C([2H])C([2H])=C2C(C[C@H](N)C(O)=O)=C([2H])NC2=C1[2H] QIVBCDIJIAJPQS-HLTLGYGQSA-N 0.000 claims description 3
- DDRJAANPRJIHGJ-FIBGUPNXSA-N 2-Amino-3-(trideuteriomethyl)-4H-imidazol-5-one Chemical compound [2H]C([2H])([2H])N1CC(=O)N=C1N DDRJAANPRJIHGJ-FIBGUPNXSA-N 0.000 claims description 3
- JFLIEFSWGNOPJJ-CJMNRESHSA-N (2s)-5-amino-5-oxo-2-[[2-(2,3,4,5,6-pentadeuteriophenyl)acetyl]amino]pentanoic acid Chemical compound [2H]C1=C([2H])C([2H])=C(CC(=O)N[C@@H](CCC(N)=O)C(O)=O)C([2H])=C1[2H] JFLIEFSWGNOPJJ-CJMNRESHSA-N 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- 239000012071 phase Substances 0.000 description 147
- 239000012491 analyte Substances 0.000 description 106
- 239000000523 sample Substances 0.000 description 96
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 87
- 238000004587 chromatography analysis Methods 0.000 description 82
- 229960004799 tryptophan Drugs 0.000 description 74
- 210000002966 serum Anatomy 0.000 description 57
- 238000003908 quality control method Methods 0.000 description 55
- 210000002381 plasma Anatomy 0.000 description 54
- 238000004885 tandem mass spectrometry Methods 0.000 description 48
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 46
- -1 N-acetylsthreonine Chemical compound 0.000 description 38
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 38
- 238000000926 separation method Methods 0.000 description 38
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 37
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 36
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 36
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 35
- 229960000367 inositol Drugs 0.000 description 35
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 35
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 description 29
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 28
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 28
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000007789 gas Substances 0.000 description 27
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 230000014759 maintenance of location Effects 0.000 description 24
- 238000011084 recovery Methods 0.000 description 24
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 23
- 235000019253 formic acid Nutrition 0.000 description 23
- 239000004202 carbamide Substances 0.000 description 19
- 238000002552 multiple reaction monitoring Methods 0.000 description 19
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 18
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 18
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 description 18
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 18
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 18
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 17
- 238000010828 elution Methods 0.000 description 16
- 238000013467 fragmentation Methods 0.000 description 16
- 238000006062 fragmentation reaction Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 238000001360 collision-induced dissociation Methods 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 9
- 239000005695 Ammonium acetate Substances 0.000 description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
- 229940043376 ammonium acetate Drugs 0.000 description 9
- 235000019257 ammonium acetate Nutrition 0.000 description 9
- 239000000908 ammonium hydroxide Substances 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 8
- 238000004807 desolvation Methods 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 239000006199 nebulizer Substances 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 7
- 238000000132 electrospray ionisation Methods 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000003190 augmentative effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 5
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000013375 chromatographic separation Methods 0.000 description 4
- 230000024924 glomerular filtration Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- CPXSBHKDEPPWIX-MKWJWUHGSA-N (2S)-2-amino-3-[2-[(3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-1H-indol-3-yl]propanoic acid Chemical compound C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)C1=C(C[C@H](N)C(=O)O)C2=CC=CC=C2N1 CPXSBHKDEPPWIX-MKWJWUHGSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- HEBKCHPVOIAQTA-WCMJATGVSA-N (2R,4R)-(1,2,3,4,5-13C5)pentane-1,2,3,4,5-pentol Chemical compound [13CH2]([13C@@H](O)[13C@H](O)[13C@H](O)[13CH2]O)O HEBKCHPVOIAQTA-WCMJATGVSA-N 0.000 description 2
- CPXSBHKDEPPWIX-RAYCSJGISA-N 2'-alpha-mannosyl-L-tryptophan Chemical compound N1C2=CC=CC=C2C(C[C@H](N)C(O)=O)=C1[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O CPXSBHKDEPPWIX-RAYCSJGISA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000012192 Cystatin C Human genes 0.000 description 2
- 108010061642 Cystatin C Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JJIHLJJYMXLCOY-UHFFFAOYSA-N N-Acetyl-DL-serine Chemical compound CC(=O)NC(CO)C(O)=O JJIHLJJYMXLCOY-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- MDAWATNFDJIBBD-UHFFFAOYSA-M potassium;1h-indol-3-yl sulfate Chemical compound [K+].C1=CC=C2C(OS(=O)(=O)[O-])=CNC2=C1 MDAWATNFDJIBBD-UHFFFAOYSA-M 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000002553 single reaction monitoring Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012421 spiking Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- JDHILDINMRGULE-FYFSCIFKSA-N (2S)-2-amino-3-[3-(trideuteriomethyl)imidazol-4-yl]propanoic acid Chemical compound C(N1C=NC=C1C[C@H](N)C(=O)O)([2H])([2H])[2H] JDHILDINMRGULE-FYFSCIFKSA-N 0.000 description 1
- QJYMWMDDBANNAM-QXYVSOOMSA-N (2S)-2-deuterio-2-(dideuterioamino)-3-hydroxy-4-oxopentanoic acid Chemical compound C(C)(=O)C([C@](N([2H])[2H])(C(=O)O)[2H])O QJYMWMDDBANNAM-QXYVSOOMSA-N 0.000 description 1
- KAXRWMOLNJZCEW-QRPNPIFTSA-N (2s)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid;sulfuric acid Chemical compound OS(O)(=O)=O.OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N KAXRWMOLNJZCEW-QRPNPIFTSA-N 0.000 description 1
- CDAISMWEOUEBRE-MZWXYZOWSA-N 1,2,3,4,5,6-hexadeuteriocyclohexane-1,2,3,4,5,6-hexol Chemical compound [2H]C1(O)C([2H])(O)C([2H])(O)C([2H])(O)C([2H])(O)C1([2H])O CDAISMWEOUEBRE-MZWXYZOWSA-N 0.000 description 1
- MMGJNINGVUMRFI-UHFFFAOYSA-N 15686-38-1 Chemical compound C1CC2(C3=C(C4=CC=CC=C4N3)C3)CCCCC2C3N1CC1CC1 MMGJNINGVUMRFI-UHFFFAOYSA-N 0.000 description 1
- PEDXUVCGOLSNLQ-LUAMTSQFSA-N 2-deuterio-2-[deuterio-(2,2,2-trideuterioacetyl)amino]-3-hydroxybutanoic acid Chemical compound C(C([2H])([2H])[2H])(=O)N(C(C(O)C)(C(=O)O)[2H])[2H] PEDXUVCGOLSNLQ-LUAMTSQFSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CYZKJBZEIFWZSR-LURJTMIESA-N N(alpha)-methyl-L-histidine Chemical compound CN[C@H](C(O)=O)CC1=CNC=N1 CYZKJBZEIFWZSR-LURJTMIESA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- KTHDTJVBEPMMGL-UHFFFAOYSA-N N-acetyl-L-alanine Natural products OC(=O)C(C)NC(C)=O KTHDTJVBEPMMGL-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000048176 Prostaglandin-D synthases Human genes 0.000 description 1
- 108030003866 Prostaglandin-D synthases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- XSQUKJJJFZCRTK-OUBTZVSYSA-N Urea-13C Chemical compound N[13C](N)=O XSQUKJJJFZCRTK-OUBTZVSYSA-N 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- XSQUKJJJFZCRTK-VMIGTVKRSA-N bis(azanyl)methanone Chemical compound [15NH2][13C]([15NH2])=O XSQUKJJJFZCRTK-VMIGTVKRSA-N 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 229940029378 iothalamate Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000012627 multivariate algorithm Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0009—Calibration of the apparatus
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0027—Methods for using particle spectrometers
- H01J49/0031—Step by step routines describing the use of the apparatus
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/004—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn
- H01J49/0045—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn characterised by the fragmentation or other specific reaction
- H01J49/005—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn characterised by the fragmentation or other specific reaction by collision with gas, e.g. by introducing gas or by accelerating ions with an electric field
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/10—Ion sources; Ion guns
- H01J49/14—Ion sources; Ion guns using particle bombardment, e.g. ionisation chambers
- H01J49/145—Ion sources; Ion guns using particle bombardment, e.g. ionisation chambers using chemical ionisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7057—(Intracellular) signaling and trafficking pathways
- G01N2800/7066—Metabolic pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Diabetes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435967P | 2016-12-19 | 2016-12-19 | |
| US62/435,967 | 2016-12-19 | ||
| US201762526043P | 2017-06-28 | 2017-06-28 | |
| US62/526,043 | 2017-06-28 | ||
| US201762558014P | 2017-09-13 | 2017-09-13 | |
| US62/558,014 | 2017-09-13 | ||
| PCT/US2017/066364 WO2018118630A1 (en) | 2016-12-19 | 2017-12-14 | Mass spectrometry assay method for detection and quantitation of kidney function metabolites |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502544A JP2020502544A (ja) | 2020-01-23 |
| JP2020502544A5 JP2020502544A5 (enExample) | 2021-01-21 |
| JP7393206B2 true JP7393206B2 (ja) | 2023-12-06 |
Family
ID=62627087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553158A Active JP7393206B2 (ja) | 2016-12-19 | 2017-12-14 | 腎機能代謝産物の検出及び定量化のための質量分析アッセイ方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11619636B2 (enExample) |
| EP (1) | EP3555615B9 (enExample) |
| JP (1) | JP7393206B2 (enExample) |
| CN (1) | CN110088615B (enExample) |
| AU (1) | AU2017382744B2 (enExample) |
| CA (1) | CA3045022C (enExample) |
| ES (1) | ES3004083T3 (enExample) |
| WO (1) | WO2018118630A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3555615B9 (en) | 2016-12-19 | 2025-03-19 | Metabolon, Inc. | Mass spectrometry assay method for detection and quantitation of kidney function metabolites |
| CA3110864A1 (en) * | 2018-09-11 | 2020-03-19 | Metabolon, Inc. | Mass spectrometry assay method for detection and quantitation of microbiota-related metabolites |
| US20220189751A1 (en) * | 2019-04-24 | 2022-06-16 | Shimadzu Corporation | Imaging mass spectrometer |
| CN113892029A (zh) * | 2019-05-31 | 2022-01-04 | 梅塔博隆股份有限公司 | 用于检测代谢物的质谱分析方法 |
| CN112946150B (zh) * | 2019-11-26 | 2024-06-18 | 深圳华大临床检验中心 | 一种快速检测人体尿液中高香草酸、香草扁桃酸、5-羟基吲哚乙酸及肌酐的方法及试剂盒 |
| CN111007173A (zh) * | 2019-12-20 | 2020-04-14 | 辉源生物科技（上海）有限公司 | 吲哚胺2，3-二氧化酶抑制剂的筛选方法 |
| WO2021232211A1 (zh) * | 2020-05-19 | 2021-11-25 | 深圳市中医院 | 诊断肾病的标志物以及诊断方法 |
| CN115917323A (zh) * | 2020-05-19 | 2023-04-04 | 赛诺菲 | 使用干血样验证药物水平的方法 |
| CN114518413B (zh) * | 2020-11-18 | 2024-12-31 | 江苏天士力帝益药业有限公司 | 一种卡托普利原料药中脯氨酸的含量测定方法 |
| CN114216984B (zh) * | 2021-12-16 | 2023-10-13 | 川北医学院附属医院 | 一种骨质疏松症负离子诊断标志物及其检测方法 |
| CN114414700A (zh) * | 2022-01-27 | 2022-04-29 | 重庆迪纳利医药科技有限责任公司 | 一种同时测定生物样品中多种内源性糖醇含量的方法和系统 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011511276A (ja) | 2008-01-31 | 2011-04-07 | ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド | マスアナライザーに連結されるレーザー脱離イオン源を用いる代謝障害のハイスループットスクリーニング |
| JP2016520192A (ja) | 2013-05-14 | 2016-07-11 | メタボロン，インコーポレイテッド | 腎機能に関連付けられるバイオマーカーおよびそれを使用する方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5624709B2 (ja) * | 2008-03-13 | 2014-11-12 | 大日本住友製薬株式会社 | 内因性代謝物の分析方法 |
| JP5197846B2 (ja) * | 2009-04-30 | 2013-05-15 | 紀陽 田仲 | 腎疾患重篤度を判定する方法又は装置若しくはその作動方法 |
| EP3511973B1 (en) * | 2010-12-28 | 2021-08-04 | Quest Diagnostics Investments LLC | Quantitation of insulin by mass spectrometry |
| EP2788763A4 (en) * | 2011-12-09 | 2015-10-07 | Metabolon Inc | BIOMARKERS FOR RENAL CANCER AND METHODS OF USE |
| CN102680599A (zh) * | 2012-05-11 | 2012-09-19 | 上海特敏生物医药科技有限公司 | 尿肌氨酸及肌酐测定试剂盒 |
| WO2014120449A1 (en) * | 2013-01-31 | 2014-08-07 | Metabolon, Inc. | Biomarkers related to insulin resistance progression and methods using the same |
| CN105143872B (zh) * | 2013-06-07 | 2019-03-01 | 皮尔斯生物科技有限公司 | 通过质谱分析用复用内标物对蛋白质和蛋白质修饰的绝对定量 |
| ES2731678T3 (es) * | 2013-07-31 | 2019-11-18 | Pharnext | Herramientas de diagnóstico para la enfermedad de Alzheimer |
| US20170276669A1 (en) * | 2014-08-15 | 2017-09-28 | The Johns Hopkins University | Precise estimation of glomerular filtration rate from multiple biomarkers |
| CN105738626B (zh) * | 2014-12-12 | 2017-07-14 | 中国科学院大连化学物理研究所 | 一种新的血清代谢物的组合及其作为肝癌诊断标志物的用途 |
| EP3278100B1 (en) * | 2015-03-28 | 2023-06-14 | Tecan SP, Inc. | Methods and uses comprising solid phase extraction, derivatization with crown ethers, and mass spectrometry |
| CN107850568A (zh) * | 2015-05-27 | 2018-03-27 | 奎斯特诊断投资有限公司 | 用于质谱定量由微量取样装置提取的分析物的方法 |
| CN104897821A (zh) * | 2015-06-03 | 2015-09-09 | 福建中烟工业有限责任公司 | 提取样品中肌醇的方法、试剂盒及其用途 |
| EP3555615B9 (en) | 2016-12-19 | 2025-03-19 | Metabolon, Inc. | Mass spectrometry assay method for detection and quantitation of kidney function metabolites |
-
2017
- 2017-12-14 EP EP17885159.8A patent/EP3555615B9/en active Active
- 2017-12-14 US US16/466,451 patent/US11619636B2/en active Active
- 2017-12-14 CN CN201780078615.8A patent/CN110088615B/zh active Active
- 2017-12-14 JP JP2019553158A patent/JP7393206B2/ja active Active
- 2017-12-14 AU AU2017382744A patent/AU2017382744B2/en active Active
- 2017-12-14 ES ES17885159T patent/ES3004083T3/es active Active
- 2017-12-14 CA CA3045022A patent/CA3045022C/en active Active
- 2017-12-14 WO PCT/US2017/066364 patent/WO2018118630A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011511276A (ja) | 2008-01-31 | 2011-04-07 | ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド | マスアナライザーに連結されるレーザー脱離イオン源を用いる代謝障害のハイスループットスクリーニング |
| JP2016520192A (ja) | 2013-05-14 | 2016-07-11 | メタボロン，インコーポレイテッド | 腎機能に関連付けられるバイオマーカーおよびそれを使用する方法 |
Non-Patent Citations (3)
| Title |
|---|
| ＬＣ－ＭＳ／ＭＳ－ｂａｓｅｄ ｑｕａｎｔｉｆｉｃａｔｉｏｎ ｏｆ ｋｙｎｕｒｅｎｉｎｅ ｍｅｔａｂｏｌｉｔｅｓ， ｔｒｙｐｔｏｐｈａｎ， ｍｏｎｏａｍｉｎｅｓ ａｎｄ ｎｅｏｐｔｅｒｉｎ ｉｎ ｐｌａｓｍａ， ｃｅｒｅｂｒｏｓｐｉｎａｌ ｆｌｕｉｄ ａｎｄ ｂｒａｉｎ，Ｂｉｏａｎａｌｙｓｉｓ，２０１６年８月２４日，８ （１８），ｐ．１９０３－１９１７ |
| Ｔａｎｄｅｍ ｍａｓｓ ｓｐｅｃｔｒｏｍｅｔｒｙ ｍｅａｓｕｒｅｍｅｎｔｓ ｏｆ ｃｒｅａｔｉｎｉｎｅ ｉｎ ｍｏｕｓｅ ｐｌａｓｍａ ａｎｄ ｕｒｉｎｅ ｆｏｒ ｄｅｔｅｒｍｉｎｉｎｇ ｇｌｏｍｅｒｕｌａｒ ｆｉｌｔｒａｔｉｏｎ ｒａｔｅ，Ｋｉｄｎｅｙ Ｉｎｔｅｒｎａｔｉｏｎａｌ，２００６年１２月６日，Ｖｏｌ．７１，ｐ．２６６－２７１ |
| 大気圧化学イオン化法ＬＣ／ＭＳによる食品中遊離アミノ酸の直接分析，アジレント・テクノロジーズ アプリケーション，２００６年１０月２７日，ｐ．１－５ |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110088615B (zh) | 2023-08-22 |
| JP2020502544A (ja) | 2020-01-23 |
| EP3555615B9 (en) | 2025-03-19 |
| EP3555615A1 (en) | 2019-10-23 |
| AU2017382744B2 (en) | 2023-02-09 |
| CA3045022C (en) | 2024-01-16 |
| CA3045022A1 (en) | 2018-06-28 |
| WO2018118630A1 (en) | 2018-06-28 |
| CN110088615A (zh) | 2019-08-02 |
| EP3555615A4 (en) | 2020-11-04 |
| EP3555615B1 (en) | 2024-10-30 |
| US20190346455A1 (en) | 2019-11-14 |
| ES3004083T3 (en) | 2025-03-11 |
| AU2017382744A1 (en) | 2019-06-13 |
| US11619636B2 (en) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7393206B2 (ja) | 腎機能代謝産物の検出及び定量化のための質量分析アッセイ方法 | |
| US12253532B2 (en) | Mass spectrometric quantitation assay for metabolites of leflunomide | |
| CN109564207B (zh) | 用于检测和定量代谢物的质谱方法 | |
| US11061005B2 (en) | Mass spectrometry assay method for detection and quantitation of organic acid metabolites | |
| JP2022534288A (ja) | 質量分析による抗うつ剤の定量 | |
| US11536726B2 (en) | Mass spectrometry assay method for detection and quantitation of liver function metabolites | |
| JP2018535398A (ja) | マススペクトロメトリーによるアミロイドベータの検出 | |
| JP7146895B2 (ja) | マススペクトロメトリーによるアポリポタンパク質ｅアイソタイプの検出 | |
| HK40014572B (en) | Mass spectrometry assay method for detection and quantitation of kidney function metabolites | |
| HK40014572A (en) | Mass spectrometry assay method for detection and quantitation of kidney function metabolites | |
| WO2024206847A1 (en) | Methods for quantitation of adiponectin by mass spectrometry | |
| Hankemeier | Data independent acquisition for the quantification and identification of metabolites in plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201201 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220104 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220516 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220517 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220607 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220608 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220729 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220802 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20221027 |
|
| C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20230307 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20230413 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230922 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231124 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7393206 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |